Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

The Wistar Institute patents


Recent patent applications related to The Wistar Institute. The Wistar Institute is listed as an Agent/Assignee. Note: The Wistar Institute may have other listings under different names/spellings. We're not affiliated with The Wistar Institute, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | The Wistar Institute-related inventors


Variant survivin vaccine for treatment of cancer

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (apcs) such as dendritic cells, or apc precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or apc.. . ... The Wistar Institute

Ebna1 inhibitors and their method of use

Pharmaceutical compositions of the invention comprise ebna1 inhibitors useful for the treatment of diseases caused by ebna1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise ebna1 inhibitors useful for the treatment of diseases caused by latent epstein-barr virus (ebv) infection. ... The Wistar Institute

Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer

A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (pmn-mdscs) comprises isolating from a cell suspension those cells which express lox-1 to provide a population of cells enriched with pmn-mdscs. A method of monitoring the population of lox-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. ... The Wistar Institute

Contructs for enhancing immune responses

Chimeric protein constructs including a herpesvirus glycoprotein d (gd) and a heterologous polypeptide that interact with herpes virus entry mediator (hvem) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.. . ... The Wistar Institute

Methods and compositions for treatment of metastatic and refractory cancers and tumors

A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the mek/mapk pathway that impairs t cell activation, and administering to said subject a molecule that induces t cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the mek/mapk pathway and the t cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. ... The Wistar Institute

Methods and compositions for treating cancer

A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an fshp sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (fsh) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to nkg2d. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified t cells expressing the chimeric protein, as well as method of using these compositions for the treatment of fshr-expressing cancers or tumor cells are also provided.. ... The Wistar Institute

Methods and compositions for treatment or diagnosis of cancers related to gabra3

Compositions and methods for diagnosing and treating breast cancer, including metastatic breast cancer, are provided. In one aspect, a diagnostic composition comprising a reagent which is capable of specifically complexing with, or identifying, gabra3 is provided. ... The Wistar Institute

Adenoviral vectors comprising partial deletions of e3

This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of e3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire e3 domain is deleted.. ... The Wistar Institute

Combination therapies targeting mitochondria for cancer therapy

Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises gamitrinib and a p13k inhibitor selected from px-866, azd6482, ly294002. ... The Wistar Institute

Methods and compositions for treatment of metastatic and refractory cancers and tumors

A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the mek/mapk pathway that impairs t cell activation, and administering to said subject a molecule that induces t cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the mek/mapk pathway and the t cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. ... The Wistar Institute

Small molecule hsp70 inhibitors

In an effort to discover therapies for treating hsp70 related diseases, a previously unidentified hydrophobic pocket was found in the c-terminal domain of dnak and of human hsp70. A novel chemical scaffold was also discovered for identifying compounds that treat diseases related to this hydrophobic pocket. ... The Wistar Institute

Methods and compositions for inhibiting mitochondrial trafficking

Methods for reducing, inhibiting or preventing cancer metastasis comprise blocking the movement of mitochondria within a cancer cell. Other methods involve interrupting or preventing oxidative phosphorylation pathways or respiration pathways in the cancer cell. ... The Wistar Institute

Small molecule modulators of prb inactivation

The present invention provides a small molecule treatment of diseases/conditions caused by a virus carrying a viral oncoprotein. In one embodiment, the virus which carries the viral oncoprotein is hpv. ... The Wistar Institute








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with The Wistar Institute in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for The Wistar Institute with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###